Market Research Report
Nociceptin Receptor - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||358352|
|Published||Content info||52 Pages
Delivery time: 1-2 business days
|Nociceptin Receptor - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 52 Pages||
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Nociceptin Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genito Urinary System And Sex Hormones which include indications Pain, Substance (Drug) Abuse, Dyskinesia, Somatic Pain, Alcohol Addiction, Diabetic Neuropathic Pain, Drug Addiction, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Low Back Pain, Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Overactive Bladder, Post-Operative Pain and Post-Traumatic Stress Disorder (PTSD).
Furthermore, this report also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.